ABSTRACT

Objective Sex differences in risk factors of aortic valve calcification (AVC) by echocardiography have not been reported from a large prospective study in aortic stenosis (AS).

Methods AVC was assessed using a prognostically validated visual score and grouped into none/mild or moderate/severe AVC in 1725 men and women with asymptomatic AS in the Simvastatin Ezetimibe in Aortic Stenosis study. The severity of AS was assessed by the energy loss index (ELI) taking pressure recovery in the aortic root into account.

Results More men than women had moderate/severe AVC at baseline despite less severe AS by ELI (p<0.01). Moderate/severe AVC at baseline was independently associated with lower aortic compliance and more severe AS in both sexes, and with increased high-sensitive C reactive protein (hs-CRP) only in men (all p<0.01). In Cox regression analyses, moderate/severe AVC at baseline was associated with a 2.5-fold (95% CI 1.04 to 3.06, p<0.05) higher hazard rate of major cardiovascular events in women, and a 2.2-fold higher hazard rate in men (95% CI 1.54 to 3.17) (both p<0.001), after adjustment for age, hypertension, study treatment, aortic compliance, left ventricular (LV) mass and systolic function, AS severity and hs-CRP. Moderate/severe AVC at baseline also predicted a 1.8-fold higher hazard rate of all-cause mortality in men (95% CI 1.04 to 3.06, p<0.05) independent of age, AS severity, LV mass and aortic compliance, but not in women.

Conclusion In conclusion, AVC scored by echocardiography has sex-specific characteristics in AS. Moderate/severe AVC is associated with higher cardiovascular morbidity in both sexes, and with higher all-cause mortality in men.

Trial registration number ClinicalTrials.gov identifier: NCT00092677

INTRODUCTION

Sex differences in aortic stenosis (AS) have been pointed out both at the valvular and left ventricular (LV) level.1 From the large Simvastatin Ezetimibe in Aortic Stenosis (SEAS) study, sex differences in LV adaptation during progression of AS were recently reported, despite similar rate of AS progression in both sexes.2 By multidetector CT, it was demonstrated by Aggarwal et al that women have significantly lower aortic valve calcification (AVC) load than men independent of the severity of AS.3 From this, sex-specific cut-off values for Agatston score indicating severe AS were developed and validated.3 4 Although cardiac CT more accurately measures AVC in AS and may help identify severe AS in asymptomatic patients with discordantly graded AS by conventional echocardiographic measures, it is not recommended by current guidelines as a routine test in patients with AS.5 While CT primarily quantifies areas of valvular macrocalcification, recent studies by positron emission tomography have revealed that AVC also includes inflammation and microcalcification.6 7 Since different processes involved in AVC are reflected by echocardiography and CT, AVC by echocardiography is not synonymous with AVC assessed by CT.8 The association of AVC scored by echocardiography with higher rates of combined aortic valve replacement and death has previously been documented in two studies by Rosenhek et al.9 10 However, sex-specific risk factors and prognostic implications of AVC scored by echocardiography have not been published from a large, prospective study. This was the aim of the present study.

METHODS

Study population

The present analysis of the SEAS study included the 1725 men and women (92% of the total study population) that had images available for AVC scoring on the baseline echocardiogram. Compared with ineligible patients, the patients selected for the present analysis did not differ in age, sex, prevalence of hypertension or severity of AS (all p<0.05). The SEAS study protocol, baseline characteristics and outcome have been previously published.11 12 In short, 1873 asymptomatic patients with mostly moderate AS and without known diabetes, cardiovascular or renal disease were randomised to double-blind, placebo-controlled treatment with combined ezetimibe 10 mg and simvastatin 40 mg daily for ≥4 years.12 Hypertension was defined as history of hypertension, use of antihypertensive drug treatment or blood pressure ≥140/90 mmHg at the clinic baseline visit.

Echocardiographic measurements

Echocardiography was performed using a standardised protocol in 173 study centres in seven European countries.13 14 All echocardiograms were analysed at the echocardiographic core laboratory at Haukeland University Hospital, Bergen, Norway, and 94% were proofread by the same experienced reader. Quantitative echocardiography for assessment of AVC was validated and function was.
performed following current guidelines. Previous analyses from the SEAS trial have shown excellent reproducibility for measurements of LV dimensions. Aortic valve area adjusted for pressure recovery in the aortic root (energy loss index (ELI)) was used as the primary measure of AS severity, given the superior prognostic value previously demonstrated. Aortic and mitral regurgitation were graded by colour Doppler. AVC was graded as none (no calcification), mild (isolated small spots), moderate (multiple bigger spots) and severe (extensive calcification of all cusps). LV mass was calculated using an autopsy validated formula. LV hypertrophy was considered present if LV mass/height2.7 was ≥49.2 g/m2.7 in men and 46.7 g/m2.7 in women. LV systolic function was assessed by biplane Simpson’s ejection fraction and by midwall shortening adjusted for circumferential end-systolic stress taking the mean transaortic valve gradient into account (stress-corrected midwall shortening (scMWS)). Aortic compliance was assessed from LV stroke volume/pulse pressure ratio.

Study outcomes
The primary outcome of the SEAS study was major cardiovascular events, a composite endpoint consisting of aortic valve-related events (combined aortic valve replacement, congestive heart failure due to AS and cardiovascular death) and ischaemic cardiovascular events (combined non-fatal myocardial infarction, non-haemorrhagic stroke, coronary revascularisation, hospitalisation for unstable angina pectoris and cardiovascular death). Secondary outcomes included aortic valve events and ischaemic cardiovascular events analysed separately. All-cause mortality was a tertiary endpoint. All outcomes were classified by an independent endpoint classification committee blinded to study-group assignment.

Ethics approval
The SEAS study was approved by ethics committees in all participating study centres, and all patients provided written informed consent.

Statistical analyses
Statistical analyses were performed using IBM SPSS 23.0. Patients were grouped according to sex and the baseline severity of AVC (none/mild vs moderate/severe AVC). Continuous variables are given as mean±SD and categorical variables as percentages. Differences between groups were tested by analysis of variance with Scheffe’s post hoc test and Bonferroni adjustment.

The intraclass correlation coefficient was used to assess both intraobserver and interobserver variability for the AVC score. Intraobserver variability was assessed in 500 randomly selected patients scored twice by one experienced sonographer (GC), several weeks apart. Interobserver variability was assessed in 150 randomly selected patients analysed twice by an experienced and less experienced reader (DC), respectively. Agreement between AVC scores was assessed by the Bland–Altman method using the 95% limits of agreement and the variation coefficient of the mean difference.

Binary logistic regression analyses reported as OR and 95% CIs were used to identify risk factors of AVC in women and men. Based on the logistic regression analyses, a propensity score for AVC was derived both in women and in men using the AVC score as dependent variable and age, aortic compliance, ELI, high-sensitive C reactive protein (hs-CRP) and scMWS as independent variables. The propensity scores reflect the likelihood that an individual patient would develop moderate/severe AVC versus none/mild AVC given all the other known variables other than the outcome variable. The association of AVC severity with study outcomes was tested in Kaplan-Meier plots with log-rank test and in multivariable Cox regression analyses with results reported as HR and 95% CI. We determined the interaction between gender and AVC by introducing the cross product of the two variables in the Cox regression analysis for major cardiovascular events. Further on, we run the multivariate Cox model separately in women and men and with adjustment for age, hypertension, LV mass index, ELI, aortic compliance, hs-CRP, scMWS and study treatment allocation. The respective covariates were selected based on a stepwise backward procedure. Additionally, the propensity scores for AVC were forced into the Cox models to account for gender differences in the distribution of the respective covariates. We examined the validity of the proportionality assumption by testing the significance of the covariate–time interaction terms. The variables included in the Cox analyses did not violate the proportionality assumption.

A p value <0.05 was considered statistical significant in all analyses.

Figure 1  Bland-Altman analyses of the aortic valve calcification (AVC) visual score measured by two different readers (A) and twice by the same reader (B) with the mean value of the difference between measurements (the solid reference line in each panel) and 95% limits of agreement (the dotted lines in each panel).
Valvular heart disease

Table 1  Clinical, biochemical and echocardiographical characteristics of women and men grouped according to aortic valve calcification (AVC) severity at baseline

<table>
<thead>
<tr>
<th></th>
<th>Women (N=664)</th>
<th></th>
<th>Men (N=1061)</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>None/mild AVC(n=247)</td>
<td>Moderate/severe AVC(n=417)</td>
<td>None/mild AVC(n=322)</td>
<td>Moderate/severe AVC(n=739)</td>
</tr>
<tr>
<td>Age (years)</td>
<td>68.2±9.4*</td>
<td>69.9±9.3†</td>
<td>65.3±9.8</td>
<td>66.6±9.5†</td>
</tr>
<tr>
<td>Body mass index (kg/m²)</td>
<td>27.5±5.4</td>
<td>26.5±5.1†</td>
<td>27.1±3.6</td>
<td>26.8±3.9</td>
</tr>
<tr>
<td>Hypertension</td>
<td>89%‡</td>
<td>88%‡</td>
<td>79%</td>
<td>81%</td>
</tr>
<tr>
<td>Antihypertensive treatment (%)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Calcium antagonists</td>
<td>36</td>
<td>31</td>
<td>36</td>
<td>32</td>
</tr>
<tr>
<td>ACE inhibitors</td>
<td>32</td>
<td>27</td>
<td>35</td>
<td>32</td>
</tr>
<tr>
<td>Angiotensin receptor blockers</td>
<td>21</td>
<td>21</td>
<td>19</td>
<td>18</td>
</tr>
<tr>
<td>Diuretics</td>
<td>52§</td>
<td>52</td>
<td>35</td>
<td>46</td>
</tr>
<tr>
<td>Beta-blockers</td>
<td>43</td>
<td>42</td>
<td>37</td>
<td>39</td>
</tr>
<tr>
<td>No of antihypertensive agents</td>
<td>1.4§</td>
<td>1.3³</td>
<td>1.1</td>
<td>1.2</td>
</tr>
<tr>
<td>Systolic blood pressure (mmHg)</td>
<td>150±20†</td>
<td>151±21*</td>
<td>145±19</td>
<td>143±19</td>
</tr>
<tr>
<td>Diastolic blood pressure (mmHg)</td>
<td>81±10</td>
<td>82±10</td>
<td>82±10</td>
<td>82±10</td>
</tr>
<tr>
<td>Heart rate (beats/min)</td>
<td>69±11*</td>
<td>68±11*</td>
<td>65±12</td>
<td>64±11</td>
</tr>
<tr>
<td>Total cholesterol (mmol/L)</td>
<td>6.0±1.0*</td>
<td>6.0±1.1*</td>
<td>5.6±0.9</td>
<td>5.5±1.0</td>
</tr>
<tr>
<td>LDL cholesterol (mmol/L)</td>
<td>3.7±0.9</td>
<td>3.7±0.9</td>
<td>3.6±0.8</td>
<td>3.5±0.9</td>
</tr>
<tr>
<td>Creatine (µmol/L)</td>
<td>84±13*</td>
<td>85±14*</td>
<td>98±14</td>
<td>99±15</td>
</tr>
<tr>
<td>hs-CRP (mg/dL)</td>
<td>0.26 (0.10–0.49)</td>
<td>0.24 (0.10–0.48)</td>
<td>0.18 (0.08–0.31)</td>
<td>0.20 (0.08–0.44)§</td>
</tr>
<tr>
<td>Peak aortic jet velocity (m/s)</td>
<td>2.64±0.34</td>
<td>3.33±0.46†</td>
<td>2.62±0.36</td>
<td>3.32±0.49†</td>
</tr>
<tr>
<td>Mean transvalvular gradient (mmHg)</td>
<td>16±4</td>
<td>27±8†</td>
<td>16±5</td>
<td>26±9§</td>
</tr>
<tr>
<td>Aortic valve area (cm²)</td>
<td>1.28±0.38*</td>
<td>1.02±0.32*‡</td>
<td>1.64±0.55</td>
<td>1.27±0.43†</td>
</tr>
<tr>
<td>Aortic valve area index (cm²/m²)</td>
<td>0.72±0.21*</td>
<td>0.59±0.19**</td>
<td>0.82±0.28</td>
<td>0.64±0.21†</td>
</tr>
<tr>
<td>Energy loss index (cm²/m²)</td>
<td>1.06±0.54</td>
<td>0.77±0.33‡</td>
<td>1.13±0.57</td>
<td>0.83±0.42‡</td>
</tr>
<tr>
<td>Ejection fraction (%)</td>
<td>67±6</td>
<td>66±7</td>
<td>67±7</td>
<td>66±7‡</td>
</tr>
<tr>
<td>scMWS (%)</td>
<td>102±19§</td>
<td>99±20†</td>
<td>98±19</td>
<td>94±19**</td>
</tr>
<tr>
<td>LV mass index (g/m³)</td>
<td>41.9±12.4*</td>
<td>44.2±14.0*</td>
<td>45.3±15.7</td>
<td>47.9±14.7†</td>
</tr>
<tr>
<td>Stroke volume/pulse pressure (ml/mmHg)</td>
<td>3.25±1.51*</td>
<td>3.07±1.34*</td>
<td>4.54±2.17</td>
<td>4.21±2.00†</td>
</tr>
<tr>
<td>Mitral regurgitation</td>
<td>64%</td>
<td>70%*</td>
<td>55%</td>
<td>54%</td>
</tr>
<tr>
<td>Aortic regurgitation</td>
<td>65%‡</td>
<td>72%‡</td>
<td>82%</td>
<td>84%</td>
</tr>
</tbody>
</table>

*p<0.001, **p<0.01, †p<0.05 between groups with none/mild versus moderate/severe AVC within same sex, ‡p<0.01, §p<0.05 between sexes, ¶p<0.001 .

hs-CRP, high-sensitive C reactive protein; LDL, low-density lipid; LV, left ventricular; scMWS, stress-corrected midwall shortening.

RESULTS

Patient demographics

Reproductibility of the AVC visual scoring was excellent with an intraobserver agreement of 0.95 and interobserver agreement of 0.92. There was good interobserver (variation coefficient 4.7%, 95% limits of agreement −1.05 to 1.24) and intraobserver (variation coefficient 2.5%, 95% limits of agreement −1.91 to 1.27) agreement for scoring of AVC (figure 1). At baseline, moderate/severe AVC was found in 63% of women and 70% of men (p<0.01) (table 1). Irrespective of AVC severity, women were older, had higher scMWS and lower LV mass index, aortic valve area index and aortic compliance, and included more subjects with hypertension compared with men (all p<0.05) (table 1).

Antihypertensive treatment did not differ between sexes except for higher use of diuretics among women in patients with none/mild AVC (p<0.05). Both men and women with moderate/severe AVC at baseline had higher LV mass index and lower scMWS compared with their none/mild AVC counterparts (all p<0.05). In the same AVC category, AS assessed by ELI was consistently more severe in women than in men (figure 2). Among men, moderate/severe AVC had higher hs-CRP compared with the none/mild AVC group (p<0.05) (table 1).

In logistic regression analyses, moderate/severe AVC was associated with lower aortic compliance and more severe AS in both sexes (both p<0.01) and with higher serum hs-CRP in men (p<0.01) (table 2). In subsequent regression analyses, no association between AVC and serum cholesterol or mitral and aortic valve regurgitation were found when they were added to the covariates (all p>0.05).

AVC and outcome

In Kaplan-Meier tests, moderate/severe AVC at baseline predicted higher rates of major cardiovascular events during a median of 4.3 years follow-up in both sexes and higher all-cause mortality in men (all p<0.05) (figure 3).

In multivariate Cox analyses, adjusting for differences in baseline characteristics between groups and known prognosticators in AS including age, hypertension, scMWS, LV mass index, aortic compliance, ELI, hs-CRP, randomised study treatment allocation, as well as the propensity scores for AVC, presence of baseline moderate/severe AVC was associated with higher HR of combined major cardiovascular events and aortic valve events in both sexes (table 3). In further Cox analyses, the results remained...
Valvular heart disease

Figure 2  Severity of aortic stenosis by the energy loss index assessed in women and men and in the two aortic valve calcification (AVC) subgroups: no/mild AVC and moderate/severe AVC. p value <0.05 between women and men in each AVC category.

unchanged when total cholesterol, mitral or aortic regurgitation and type of antihypertensive medication were added to the covariates. In subsequent Cox analyses, presence of moderate/severe AVC at baseline was associated with increased all-cause mortality only in men and increased hazard of ischaemic cardiovascular events only in women (table 3).

DISCUSSION

This post hoc analysis within the large SEAS study is the first to demonstrate that AVC in AS scored by echocardiography has sex-specific risk factors and that presence of moderate/severe AVC at baseline predicts higher rates of major cardiovascular events and combined aortic valve replacement and death both in women and men. Our sex-specific findings add to previous reports by Rosenhek et al.29 30 Furthermore, in this study, an independent association with higher all-cause mortality was found only in men and with higher risk of ischaemic cardiovascular events only in women. Of note, these associations persisted after adjustment in multivariate models for important confounders including age,9 hypertension,24 AS severity,9 10 aortic compliance, LV structure and systolic function,20 hs-CRP and randomised study treatment.

The value of AVC assessment by echocardiography has been debated after development of a quantitative method to assess valvular macrocalcification by CT.8 The main question about the usefulness of echocardiography in assessment of AVC has been related to reproducibility. As demonstrated by this study, both intraobserver and interobserver reproducibility was excellent. It has been demonstrated that AVC by echocardiography, despite grossly correlated with CT findings, reveals a higher calcification degree than computer tomography, and that the 4-point classification system classifies patients with AS in four classes that partly overlap in AVC score by CT.8 These differences are, in our view, inherent to the physics of ultrasound and X-ray that by their nature reveal partially different types of tissue lesion. While CT allows a quantitative measurement of macrocalcifications, the echocardiographic AVC scoring assesses semiquantitatively the presence of hyperechoic zones that probably also include areas of microcalcification and inflammation.6 7 While we acknowledge the diagnostic value CT can have in certain groups of patients with AS, as those with low-flow, low-grade AS with normal ejection fraction,25 we believe echocardiography to be the only feasible method to be applied in regular follow-up of the majority of patients with AS outside specialised heart valve centres. As demonstrated in the present analysis, assessment of AVC by echocardiography is reliable and of prognostic value both in women and men, independent of traditional prognostic markers in AS. Our findings add to previous documentation from an international registry showing that AVC by CT was associated with increased mortality in both sexes.4

Our finding that moderate/severe AVC was less prevalent in women than men despite comparable AS severity adds to previous studies on AVC by echocardiography,9 10 and confirms previous observations by CT using the Agatston score.3 4 Differences in body surface area, aortic valve weight and aortic annulus size documented by previous studies may contribute to explain these sex differences.26 The association of AVC with lower aortic compliance underlines the systemic arterial involvement in degenerative AS.27

Hs-CRP and elevated serum creatine are well-known factors associated with atherosclerosis. This study found that higher AVC was associated with more severe AS in both sexes, and with serum hs-CRP particularly in men. In contrast, the Olmsted County study did not find any relation between hs-CRP levels and AS severity or the degree of valve calcification.28 The Chronic Renal Insufficiency Cohort study reported an inversely relation between AVC and estimated glomerular filtration rate in patients with non-end-stage chronic kidney disease.29 However, when adjusted for cardiovascular risk factors such as CRP and homocysteine, the association became non-significant. Recently published research demonstrates proinflammatory and procoagulation changes in the plasma of patients with AS.30 Our study additionally reveals an independent association between the systemic inflammatory marker hs-CRP and AVC only in men, while no association between AVC and serum creatine or estimated glomerular filtration rate was found.

Table 2  Independent risk factors of moderate/severe AVC in women and men

<table>
<thead>
<tr>
<th>Covariate</th>
<th>Women</th>
<th>Men</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td>OR (95% CI)</td>
<td>p Value</td>
</tr>
<tr>
<td></td>
<td>1.02 (1.00 to 1.04)</td>
<td>0.310</td>
</tr>
<tr>
<td>Aortic compliance (mL/mmHg)</td>
<td>0.77 (0.66 to 0.91)</td>
<td>0.002</td>
</tr>
<tr>
<td>ELI (cm²/m²)</td>
<td>0.11 (0.06 to 0.20)</td>
<td>&lt;0.001</td>
</tr>
<tr>
<td>Hs-CRP (mg/dL)</td>
<td>1.26 (0.92 to 1.72)</td>
<td>0.146</td>
</tr>
<tr>
<td>scMWS (%)</td>
<td>0.99 (0.98 to 1.00)</td>
<td>0.234</td>
</tr>
</tbody>
</table>

ELI, energy loss index; hs-CRP, high-sensitive C reactive protein; scMWS, stress-corrected midwall shortening.
Valvular heart disease

Study limitations

The SEAS study excluded patients with known coronary heart disease, heart failure, diabetes mellitus, renal failure, history of stroke, peripheral vascular disease and patients with indication for lipid-lowering therapy. Thus, projection of results to less selective AS patients should be done with caution. AVC is assessed semiquantitatively by echocardiography. We acknowledge the value of CT in quantitative assessment of valvular macrocalcifications. However, as demonstrated, echocardiographic assessment of AVC was highly reproducible both for experienced and less experienced sonographers and may be more available and feasible in clinical cardiology practice. However, further studies are needed to directly compare performance and prognostic value of AVC scored by echocardiography and CT.

Figure 3  Kaplan-Meier curves reporting survival free of major cardiovascular events (A), and survival (B) in women (left panels) and men (right panels). AVC, aortic valve calcification.

Table 3  The association of baseline moderate/severe aortic valve calcification with study outcomes in women and men

<table>
<thead>
<tr>
<th></th>
<th>Women</th>
<th></th>
<th>Men</th>
<th></th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>n</td>
<td>HR (95% CI)</td>
<td>p Value</td>
<td>n</td>
</tr>
<tr>
<td>Major cardiovascular events</td>
<td>172</td>
<td>2.50 (1.64 to 3.80)</td>
<td>&lt;0.001</td>
<td>270</td>
</tr>
<tr>
<td>Aortic valve events</td>
<td>162</td>
<td>2.44 (1.58 to 3.76)</td>
<td>&lt;0.001</td>
<td>246</td>
</tr>
<tr>
<td>Ischaemic cardiovascular events</td>
<td>70</td>
<td>1.86 (1.01 to 3.44)</td>
<td>0.047</td>
<td>141</td>
</tr>
<tr>
<td>All-cause mortality*</td>
<td>47</td>
<td>1.40 (0.70 to 2.79)</td>
<td>0.338</td>
<td>96</td>
</tr>
<tr>
<td>Aortic valve replacement or death</td>
<td>170</td>
<td>2.19 (1.46 to 3.30)</td>
<td>&lt;0.001</td>
<td>279</td>
</tr>
</tbody>
</table>

* Model adjusted for age, energy loss index, aortic compliance and left ventricular mass index.

n, number of events.

CONCLUSION
In conclusion, in patients with AS and without diabetes mellitus or known renal or cardiovascular disease participating in the SEAS study, presence of moderate/severe AVC by echocardiography at baseline was associated with higher hazard rates of major cardiovascular events and combined aortic valve replacement and death in both sexes, with higher hazard rates of ischaemic cardiovascular events in women and with higher all-cause mortality in men. These associations were independent of important confounders including older age, hypertension, aortic compliance, AS severity and LV structure and function.

Key messages

What is already known on this subject?
Sex-specific risk factors of aortic valve calcification (AVC) scored by echocardiography and its prognostic relevance in women and men with aortic stenosis (AS) have not been previously reported from a large, prospective study.

What might this study add?
This post hoc analysis within the Simvastatin Ezetimibe in Aortic Stenosis study is the first to demonstrate sex-specific risk factors of AVC scored by echocardiography. Moderate/severe AVC at study baseline independently predicted higher rates of major cardiovascular events and combined death and aortic valve replacement in both sexes, higher hazard rate of ischaemic cardiovascular events only in women, and higher all-cause mortality only in men.

How might this impact on clinical practice?
Assessment of AVC by echocardiography is highly reproducible and of prognostic value in the follow-up of women and men with AS, independent of traditional prognostic markers.

Correction notice
Since this paper was first published online the author name Constantino Mancusi has been updated to Constantino Mancusi.

Contributors
HKT, GC, EG and DC were involved in the conception and design, as well as in the analysis and interpretation of data. All authors have revised the manuscript critically and approved it for submission.

Competing interests
None declared.

Patient consent
Obtained.

Ethics approval
The SEAS study was approved by ethics committees in all participating study centers, and all patients provided written informed consent.

Provenance and peer review
Not commissioned; externally peer reviewed.

Open Access
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

REFERENCES

Echocardiographic aortic valve calcification and outcomes in women and men with aortic stenosis

Henrik K Thomassen, Giovanni Cioffi, Eva Gerds, Eigir Einarsen, Helga Bergljot Midtbø, Costantino Mancusi and Dana Cramariuc

*Heart* 2017 103: 1619-1624 originally published online July 11, 2017
doi: 10.1136/heartjnl-2016-311040

Updated information and services can be found at:
http://heart.bmj.com/content/103/20/1619

These include:

**References**
This article cites 29 articles, 13 of which you can access for free at:
http://heart.bmj.com/content/103/20/1619#BIBL

**Open Access**
This is an Open Access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Email alerting service**
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

**Topic Collections**
Articles on similar topics can be found in the following collections

- Open access (264)

**Notes**

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/